🔗 Share this article

Given that the US continues making unprecedented adjustments to its vaccination guidelines, a particular individual has surfaced in a surprising turn: Dr. Tracy Beth Høeg, a US-based sports physician and epidemiologist who rose to prominence by questioning Covid vaccines during the global health crisis and has concentrated on possible deaths following Covid vaccination in her short position at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Vaccine Schedule

Agency leaders were set to announce major changes to the childhood vaccine schedule in December, bringing the US with the Danish vaccine program, it is understood – a significant shift that would place the US out of step with a large portion of the international standard with little proof for improved outcomes. The planned update has been postponed until the new year.

Instead of the top vaccines chief, Høeg is scheduled to present at the meeting. She was newly appointed temporary leader of the FDA’s drug evaluation center, the fifth individual to head the office this year.

Consolidating Power at the Agency

Høeg's temporary position may indicate a closer partnership between the drug and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it signals a greater focus upon dismantling already-approved immunizations at the FDA.

The new acting director has often pushed for halting some childhood vaccine recommendations in the US in order to be more in line with Denmark's approach, a country with comprehensive healthcare and a number of inhabitants approximately the size of the state of Wisconsin.

So far public appearances, she has continued to focus on vaccines – usually the responsibility of Prasad, chief of the FDA’s CBER – instead of medication approval.

Concerns Over Expertise

The appointee has little discernible experience in pharmaceutical research, regulation or management, which has been typical for past directors of the CBER. She has been employed at the FDA as a key advisor to the agency head and CBER since spring.

“She doesn’t seem to have the necessary background” for running the CDER, stated a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She lacks experience in running a large organization. She is not an expert in pharmaceutical oversight.”

Previous commissioners of CBER would “be deeply familiar with laws and regulations and the science of drug development”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the kind of background that former directors who headed the center have had.”

The drug center has an immense workload at the FDA, she stated.

“The public just focuses on the new drug program, but the generic drug division clears a multitude of generic medications. There’s a biosimilars division, over-the-counter program and more, and each of these have to be looked after,” Woodcock noted. “The thing you overlook, that is the part that I always told people is going to bite you.”

Furthermore, a major management aspect to the job, which manages more than 5,000 staff members. “It’s a massive leadership role, if you perform it correctly,” the former official said.

Official Statement and Disputed Policies

When asked about concerns about Dr. Høeg's credentials and whether this selection signifies greater collaboration among regulatory chiefs on vaccines, a spokesperson stated that the “concerns stem from incorrect premises”.

“Her experience is consistent with the responsibilities of her position,” the official explained, citing the months Dr. Høeg spent advising the agency head on “drug safety and approval science, including computational safety modeling and shot safety tracking”.

As acting director, Høeg takes over the agency head's new fast-track approval initiative, a controversial one-day drug-approval program that reportedly concerned her former heads. “How are these therapies being selected for this expedited pathway? Who is making the decisions?” Dr. Howard questioned. “There’s a lot of secrecy happening at the FDA right now.”

Overall, he remarked, “the agency seems to be moving towards more relaxed oversight of most medications, except for shots.”

Documented Past Work on Immunizations

With vaccines, Dr. Høeg has a more documented, if troubling, past, critics have noted. She authored a study using unverified volunteer-provided data to estimate the frequency of heart inflammation following COVID-19 immunization. She counseled the Florida surgeon general Joseph Ladapo, who was said to have modified findings to indicate COVID-19 vaccines are pose a greater threat than they are.

Included in her “wish list” for the new federal leadership encompassed altering regulations for new vaccines and ending “unnecessary” vaccines, she said following the vote on a online show. At the agency, Dr. Høeg has reportedly floated the idea of excluding teenage boys from getting Covid vaccines.

“She is an thorough dogmatist who commences with her preconceived notions and tailors the evidence to retrofit the evidence in a very disingenuous, untruthful manner,” Dr. Howard stated.

Gaining Influence and a “Revenge Tour”

Høeg became part of fellow contrarians, {like|